Lantheus Holdings, Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. During the quarter, the company completed the sale of its SPECT business on January 1, 2026, and reclassified its revenue segments into Oncology, Neurology, Cardiology, and Strategic Partnerships. The company also announced a strategic program to streamline operations and focus on radiodiagnostics, incurring $7.8 million in related charges.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $377.3 million | $372.8 million |
| Gross Profit | $230.9 million | $237.7 million |
| Operating Income | $81.3 million | $102.1 million |
| Net Income | $118.4 million | $72.9 million |
| Diluted EPS | $1.80 | $1.02 |
| Operating Cash Flow | $125.1 million | $107.6 million |
| Cash and Equivalents (End of Period) | $498.6 million | $938.5 million |
| Total Debt (Long-term + Current) | $570.4 million | $569.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 1.2% year-over-year. This was driven by the inclusion of Neuraceq (Neurology) and CDMO services (from Evergreen acquisition), offset by a 6.5% decline in PYLARIFY revenue due to net sales price decreases and the divestiture of the SPECT business.
- Operating Income Decline: Operating income decreased 20.3% to $81.3 million. This was primarily due to a $10.2 million increase in Sales and Marketing expenses (driven by Neuraceq sales and PYLARIFY TruVu launch prep) and higher amortization from recent acquisitions.
- Net Income Surge: Net income increased 62.3% to $118.4 million. This significant increase was driven by a $59.3 million gain on the sale of the SPECT business and a $14.9 million unrealized gain on equity securities (Perspective Therapeutics), which offset the decline in operating income.
- Balance Sheet: Cash balances decreased significantly from Q1 2025 due to the $355.2 million upfront payment for the Lantheus Biosciences acquisition and $276.4 million for the Evergreen acquisition in 2025. However, cash increased by $139.5 million during Q1 2026, aided by proceeds from the SPECT sale.
Guidance, Outlook, and Risks
- Product Approvals: The FDA approved PYLARIFY TruVu (new formulation) in March 2026, with commercial availability expected in Q4 2026. The FDA issued tentative approval for PNT2003 (Lutetium Lu 177 Dotatate) in March 2026; final launch timing depends on patent litigation resolution.
- Regulatory Reviews: The FDA extended the review of the NDA for LNTH-2501 (neuroendocrine tumor imaging) to June 29, 2026, to review manufacturing information. The PDUFA date for MK-6240 (Alzheimer's imaging) is set for August 13, 2026.
- Strategic Shift: Management is executing a program to simplify operations, focusing on radiodiagnostics and evaluating value-maximizing alternatives for radiotherapeutic assets. $7.8 million in charges were incurred in Q1 2026 related to this program.
- Risks: Key risks include the outcome of patent litigation regarding PNT2003, the ability to secure reimbursement (TPT Status) for PYLARIFY TruVu, and the realization of contingent consideration from the SPECT business sale (up to $30 million in milestones).
Investor Verification Checklist
- SPECT Sale Contingencies: Verify the terms and likelihood of receiving the $20 million Seller Note, $20 million Deferred Cash Purchase Price, and up to $30 million in contingent milestones from Illuminated/SHINE.
- PYLARIFY Pricing Pressure: Assess the impact of the net sales price decrease on PYLARIFY margins and the timeline for transitioning customers to the new PYLARIFY TruVu formulation.
- Acquisition Integration: Review the integration progress and cost synergies from the Lantheus Biosciences (Neuraceq) and Evergreen (CDMO) acquisitions.
- Legal Proceedings: Monitor the status of the patent infringement lawsuit filed by Novartis regarding PNT2003 and the putative securities class action filed in September 2025.
- Debt Covenants: Confirm continued compliance with the 2022 Revolving Facility covenants (Interest Coverage Ratio ≥ 3.0x; Net Leverage Ratio ≤ 3.5x) given the recent strategic restructuring costs.